Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 15

1.

Discovery of [18F]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance.

Greguric I, Taylor SR, Denoyer D, Ballantyne P, Berghofer P, Roselt P, Pham TQ, Mattner F, Bourdier T, Neels OC, Dorow DS, Loc'h C, Hicks RJ, Katsifis A.

J Med Chem. 2009 Sep 10;52(17):5299-302. doi: 10.1021/jm9008423.

PMID:
19691348
2.

Preparation and biologic evaluation of a novel radioiodinated benzylpiperazine, 123I-MEL037, for malignant melanoma.

Pham TQ, Berghofer P, Liu X, Greguric I, Dikic B, Ballantyne P, Mattner F, Nguyen V, Loc'h C, Katsifis A.

J Nucl Med. 2007 Aug;48(8):1348-56. Epub 2007 Jul 13.

4.

Melanin as a potential target for radionuclide therapy of metastatic melanoma.

Dadachova E, Casadevall A.

Future Oncol. 2005 Aug;1(4):541-9. Review.

PMID:
16556030
5.

Melanoma therapy via peptide-targeted {alpha}-radiation.

Miao Y, Hylarides M, Fisher DR, Shelton T, Moore H, Wester DW, Fritzberg AR, Winkelmann CT, Hoffman T, Quinn TP.

Clin Cancer Res. 2005 Aug 1;11(15):5616-21.

6.

Alkylating benzamides with melanoma cytotoxicity.

Wolf M, Bauder-Wüst U, Mohammed A, Schönsiegel F, Mier W, Haberkorn U, Eisenhut M.

Melanoma Res. 2004 Oct;14(5):353-60.

PMID:
15457090
7.

The biology of melanocytes.

Sulaimon SS, Kitchell BE.

Vet Dermatol. 2003 Apr;14(2):57-65. Review.

PMID:
12662262
8.

123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging.

Moins N, D'Incan M, Bonafous J, Bacin F, Labarre P, Moreau MF, Mestas D, Noirault E, Chossat F, Berthommier E, Papon J, Bayle M, Souteyrand P, Madelmont JC, Veyre A.

Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1478-84. Epub 2002 Sep 11.

PMID:
12397467
9.

Progressive appearance of pigmentation in amelanotic melanoma lesions.

Cohen-Solal KA, Crespo-Carbone SM, Namkoong J, Mackason KR, Roberts KG, Reuhl KR, Chen S.

Pigment Cell Res. 2002 Aug;15(4):282-9.

PMID:
12100494
10.

Radioiodinated N-[3-(4-morpholino)propyl]-N-methyl-2-hydroxy-5-iodo-3-methylbenzylamine (ERC9): a new potential melanoma imaging agent.

Salopek TG, Scott JR, Joshua AV, Smylie M, Logus JW, Morin CA, McEwan AJ.

Eur J Nucl Med. 2001 Apr;28(4):408-17.

PMID:
11357490
11.

Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization.

Eisenhut M, Hull WE, Mohammed A, Mier W, Lay D, Just W, Gorgas K, Lehmann WD, Haberkorn U.

J Med Chem. 2000 Oct 19;43(21):3913-22.

PMID:
11052796
12.

The melanosome: the perfect model for cellular responses to the environment.

Hearing VJ.

Pigment Cell Res. 2000;13 Suppl 8:23-34.

PMID:
11041354
13.

In vitro studies on the cellular uptake of melanoma imaging aminoalkyl-iodobenzamide derivatives (ABA).

Dittmann H, Coenen HH, Zölzer F, Dutschka K, Brandau W, Streffer C.

Nucl Med Biol. 1999 Jan;26(1):51-6.

PMID:
10096501
14.

Structure distribution relationship of iodine-123-iodobenzamides as tracers for the detection of melanotic melanoma.

Brandau W, Niehoff T, Pulawski P, Jonas M, Dutschka K, Sciuk J, Coenen HH, Schober O.

J Nucl Med. 1996 Nov;37(11):1865-71.

15.

Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide).

Michelot JM, Moreau MF, Veyre AJ, Bonafous JF, Bacin FJ, Madelmont JC, Bussiere F, Souteyrand PA, Mauclaire LP, Chossat FM, et al.

J Nucl Med. 1993 Aug;34(8):1260-6.

Supplemental Content

Support Center